Metformin upregulates circadian gene PER2 to inhibit growth and enhance the sensitivity of glioblastoma cell lines to radiotherapy via SIRT2/G6PD pathway

IntroductionGlioblastoma multiform (GBM) is considered the deadliest brain cancer. Standard therapies are followed by poor patient’s survival outcomes, so novel and more efficacious therapeutic strategies are imperative to tackle this scourge. Metformin has been reported to have anti-cancer effects....

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Hailiang Li, Zheng Ma, Wanfu Yang, Yifan Zhang, Jinping Sun, Haifeng Jiang, Faxuan Wang, Li Hou, Hechun Xia
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Subjects:	glioblastoma multiform (GBM) metformin period circadian regulator 2 (PER2) silent information regulator 2 (SIRT2) glucose-6-phosphate dehydrogenase (G6PD) pentose phosphate pathway (PPP)
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1563865/full